Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dry powder inhaler with constituent rubescensin A as well as preparation method and application thereof

A technology of oridonin and dry powder inhalation, which is applied in the field of medicine, can solve problems such as allergic reactions and unreported research, and achieve the effects of high drug concentration, good fluidity, and avoiding agglomeration

Inactive Publication Date: 2011-05-18
CHINA PHARM UNIV
View PDF4 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the research on dry powder inhalation of oridonin A
[0004] In addition, the currently marketed dry powder inhalers generally use lactose as the excipient carrier. However, the impurities in lactose may cause severe allergic reactions. Therefore, it is urgent to develop dry powder inhalation preparations without lactose carriers.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Oridonin was pulverized by jet to D 90 = 2.6 µm, with D 50 The lactose of =120 microns is mixed at a mass ratio of 1:9, and after mixing evenly, the powder is packed into capsules or blisters or dry powder inhalers to obtain dry powder inhalers.

Embodiment 2

[0027] Mix Rubescensin B and micropowdered silica gel at a mass ratio of 1:1, and use airflow to pulverize to D 90 =3.5 microns, the powder is packed into capsules or blisters or dry powder inhalers to obtain dry powder inhalers.

Embodiment 3

[0029] Oridonin C was pulverized by airflow to D 90 = 3.3 µm, with D 90 = 4.2 microns of lactose, D 50 The lactose of =150 microns is mixed at a mass ratio of 1:1:7, and after mixing evenly, the powder is packed into capsules or blisters or dry powder inhalers to obtain dry powder inhalers.

[0030] Study on Pulmonary Deposition Rate of Dry Powder Inhalation

[0031] According to the method specified in the Pharmacopoeia of the People's Republic of China in 2010, the lung deposition rate of the preparation reached 25.62%. After being placed at room temperature for 24 months, the lung deposition rate of the preparation did not change significantly.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Bulk densityaaaaaaaaaa
Login to View More

Abstract

The invention relates to a dry powder inhaler with a constituent rubescensin A as well as a preparation method and application thereof. The dry powder inhaler is a medicinal composition formed by mixing the constituent rubescensin A as an active constituent with pharmaceutically acceptable excipients. Compared with orally administrated medicines, the dry powder inhaler developed by using the technical scheme provided by the invention greatly improves the effect of the constituent rubescensin A on treating esophagus cancers, lung tumors and leukemia.

Description

technical field [0001] The invention relates to a dry powder inhaler of oridonin A component, a preparation method and application thereof, and belongs to the technical field of medicine. Background technique [0002] Rabdosia rubescens, also known as Rabdosia rubescens (Hamst), is a plant belonging to the genus Lamiaceae, sweet and bitter in taste, slightly cold in nature. The whole plant is a commonly used herbal medicine in the folk, which has the functions of clearing heat and detoxification, reducing inflammation and pain, strengthening stomach and promoting blood circulation. Modern pharmacology and toxicology studies have shown that the plant has good anti-tumor effects and no obvious toxicity, and is known as "the second taxol". Five kinds of diterpenoids were isolated from the extract of the leaves of Rubescens japonicus, namely A, B, C, D and pentane, which are the main anti-cancer active ingredients, and have anti-cancer effects on esophageal cancer, lung cancer,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/72A61K9/14A61K31/122A61K31/352A61K31/357A61P35/00A61P35/02
Inventor 吕慧侠张振海
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com